International Biotechnology Trust (IBT) triumphed in an eclectic category at the Citywire Investment Trust Awards, seeing off competition from property, technology and environmental funds to be crowned best Specialist Equities trust.

 

Our awards analysed trusts’ three-year risk-adjusted performance, and on that measure, IBT has performed impressively.

 

But that performance has been amplified for shareholders thanks to a steady rerating of the shares since the announcement last year that it would pay a 4% dividend.

 

Having traded at a discount of more than 20% three years ago, the shares have this month establish a small premium to net asset value.

 

In this short video, manager Ailsa Craig reflects on a strong year for the trust and discusses a possible catalyst for the next leg of the biotechnology sector’s rally.

 

 

Read Full Article

 

Disclaimer

  • You are seeing this because you are accessing IBT’s website for the first time.

 

  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

 

  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

 

  • The material on this website is intended to be viewed only by persons resident in the EEA.

 

  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

 

  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

 

  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).